The role of the gastric fundus in glycemic control.
Bariatric surgery
Diabetes mellitus Type 2
Gastric fundus
Ghrelin
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
29
08
2022
accepted:
10
01
2023
medline:
26
5
2023
pubmed:
28
1
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
Ghrelin, one of the most studied gut hormones, is mainly produced by the gastric fundus. Abundant evidence exists from preclinical and clinical studies underlining its contribution to glucose regulation. In the following narrative review, the role of the gastric fundus in glucose regulation is summarized and we investigate whether its resection enhances glycemic control. An electronic search was conducted in the PubMed® database and in Google Scholar® using a combination of medical subject headings (MeSH). We examined types of metabolic surgery, including, in particular, gastric fundus resection, either as part of laparoscopic sleeve gastrectomy (LSG) or modified laparoscopic gastric bypass with fundus resection (LRYGBP + FR), and the contribution of ghrelin reduction to glucose regulation. Fourteen human studies were judged to be eligible and included in this narrative review. Reduction of ghrelin levels after fundus resection might be related to early glycemic improvement before significant weight loss is achieved. Long-term data regarding the role of ghrelin reduction in glucose homeostasis are sparse. The exact role of ghrelin in achieving glycemic control is still ambiguous. Data from human studies reveal a potential contribution of ghrelin reduction to early glycemic improvement, although further well-designed studies are needed.
Identifiants
pubmed: 36705877
doi: 10.1007/s42000-023-00429-7
pii: 10.1007/s42000-023-00429-7
doi:
Substances chimiques
Ghrelin
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-163Informations de copyright
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Références
Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity. Metabolism 92:6–10. https://doi.org/10.1016/j.metabol.2018.09.005
doi: 10.1016/j.metabol.2018.09.005
pubmed: 30253139
Purnell JQ (2018) Definitions, classification, and epidemiology of obesity. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–
De Lorenzo A, Romano L, Di Renzo L, Di Lorenzo N, Cenname G, Gualtieri P (2020) Obesity: a preventable, treatable, but relapsing disease. Nutrition 71:110615. https://doi.org/10.1016/j.nut.2019.110615
doi: 10.1016/j.nut.2019.110615
pubmed: 31864969
Venneri MA, Barbagallo F, Fiore D, De Gaetano R, Giannetta E, Sbardella E, Pozza C, Campolo F, Naro F, Lenzi A, Isidori AM (2019) PDE5 inhibition stimulates Tie2-expressing monocytes and Angiopoietin-1 restoring angiogenic homeostasis in diabetes. J Clin Endocrinol Metab 104(7):2623–2636. https://doi.org/10.1210/jc.2018-02525
doi: 10.1210/jc.2018-02525
pubmed: 31102457
Reijrink M, van Ark J, Lexis CPH, Visser LM, Lodewijk ME, van der Horst ICC, Zeebregts CJ, van Goor H, de Jager SCA, Pasterkamp G, Wolffenbuttel BHR, Hillebrands JL (2022) Increased frequency of proangiogenic tunica intima endothelial kinase 2 (Tie2) expressing monocytes in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol 21(1):72. https://doi.org/10.1186/s12933-022-01497-6
doi: 10.1186/s12933-022-01497-6
pubmed: 35549955
pmcid: 9102255
Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345(11):790–7. https://doi.org/10.1056/NEJMoa010492
doi: 10.1056/NEJMoa010492
pubmed: 11556298
Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL (1999) Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48(9):1836–1841. https://doi.org/10.2337/diabetes.48.9.1836
doi: 10.2337/diabetes.48.9.1836
pubmed: 10480616
Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher Oldenburg G, Cummings DE, Delegates of the 2nd Diabetes Surgery Summit (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39(6):861–877. https://doi.org/10.2337/dc16-0236
doi: 10.2337/dc16-0236
pubmed: 27222544
Cummings DE, Cohen RV (2014) Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2(2):175–181. https://doi.org/10.1016/S2213-8587(13)70198-0
doi: 10.1016/S2213-8587(13)70198-0
pubmed: 24622721
pmcid: 4160116
Madsbad S, Holst JJ (2014) GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes 63(10):3172–3174. https://doi.org/10.2337/db14-0935
doi: 10.2337/db14-0935
pubmed: 25249642
Kojima M, Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85(2):495–522. https://doi.org/10.1152/physrev.00012.2004
doi: 10.1152/physrev.00012.2004
pubmed: 15788704
Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N (2015) Bariatric Surgery Worldwide 2013. Obes Surg 25(10):1822–1832. https://doi.org/10.1007/s11695-015-1657-z
doi: 10.1007/s11695-015-1657-z
pubmed: 25835983
Alamuddin N, Vetter ML, Ahima RS, Hesson L, Ritter S, Minnick A, Faulconbridge LF, Allison KC, Sarwer DB, Chittams J, Williams NN, Hayes MR, Loughead JW, Gur R, Wadden TA (2017) Changes in fasting and prandial gut and adiposity hormones following vertical sleeve gastrectomy or Roux-en-Y-gastric bypass: an 18-month prospective study. Obes Surg 27(6):1563–1572. https://doi.org/10.1007/s11695-016-2505-5
doi: 10.1007/s11695-016-2505-5
pubmed: 28004304
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762):656–60. https://doi.org/10.1038/45230
doi: 10.1038/45230
pubmed: 10604470
Kojima M, Kangawa K (2002) Ghrelin, an orexigenic signaling molecule from the gastrointestinal tract. Curr Opin Pharmacol 2(6):665–668. https://doi.org/10.1016/s1471-4892(02)00220-5
doi: 10.1016/s1471-4892(02)00220-5
pubmed: 12482728
Ionut V, Burch M, Youdim A, Bergman RN (2013) Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring) 21(6):1093–1103. https://doi.org/10.1002/oby.20364
doi: 10.1002/oby.20364
pubmed: 23512841
Wierup N, Sundler F, Heller RS (2013) The islet ghrelin cell. J Mol Endocrinol 52(1):R35-49. https://doi.org/10.1530/JME-13-0122
doi: 10.1530/JME-13-0122
pubmed: 24049065
Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86(10):4753–8. https://doi.org/10.1210/jcem.86.10.7885
doi: 10.1210/jcem.86.10.7885
pubmed: 11600536
Fakhry J, Stebbing MJ, Hunne B, Bayguinov Y, Ward SM, Sasse KC, Callaghan B, McQuade RM, Furness JB (2019) Relationships of endocrine cells to each other and to other cell types in the human gastric fundus and corpus. Cell Tissue Res 376(1):37–49. https://doi.org/10.1007/s00441-018-2957-0
doi: 10.1007/s00441-018-2957-0
pubmed: 30467709
Lippl F, Kircher F, Erdmann J, Allescher HD, Schusdziarra V (2004) Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regul Pept 119(1–2):93–8. https://doi.org/10.1016/j.regpep.2004.01.003
doi: 10.1016/j.regpep.2004.01.003
pubmed: 15093702
Williams DL, Cummings DE, Grill HJ, Kaplan JM (2003) Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 144(7):2765–2767. https://doi.org/10.1210/en.2003-0381
doi: 10.1210/en.2003-0381
pubmed: 12810528
Sundbom M, Holdstock C, Engström BE, Karlsson FA (2007) Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg 17(3):304–310. https://doi.org/10.1007/s11695-007-9056-8
doi: 10.1007/s11695-007-9056-8
pubmed: 17546836
Perathoner A, Weiss H, Santner W, Brandacher G, Laimer E, Höller E, Aigner F, Klaus A (2009) Vagal nerve dissection during pouch formation in laparoscopic Roux-Y-gastric bypass for technical simplification: does it matter? Obes Surg 19(4):412–417. https://doi.org/10.1007/s11695-008-9657-x
doi: 10.1007/s11695-008-9657-x
pubmed: 18704604
Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50(4):707–709. https://doi.org/10.2337/diabetes.50.4.707
doi: 10.2337/diabetes.50.4.707
pubmed: 11289032
Lampropoulos C, Alexandrides T, Tsochatzis S, Kehagias D, Kehagias I (2021) Are the changes in gastrointestinal hormone secretion necessary for the success of bariatric surgery? A critical review of the literature. Obes Surg 31(10):4575–4584. https://doi.org/10.1007/s11695-021-05568-7
doi: 10.1007/s11695-021-05568-7
pubmed: 34304379
Poher AL, Tschöp MH, Müller TD (2018) Ghrelin regulation of glucose metabolism. Peptides 100:236–242. https://doi.org/10.1016/j.peptides.2017.12.015
doi: 10.1016/j.peptides.2017.12.015
pubmed: 29412824
pmcid: 5805851
Chang PC, Chen KH, Jhou HJ, Chen PH, Huang CK, Lee CH, Chang TW (2021) Promising effects of 33 to 36 Fr. bougie calibration for laparoscopic sleeve gastrectomy: a systematic review and network meta-analysis. Sci Rep 11(1):15217. https://doi.org/10.1038/s41598-021-94716-1
doi: 10.1038/s41598-021-94716-1
pubmed: 34312476
pmcid: 8313581
Chronaiou A, Tsoli M, Kehagias I, Leotsinidis M, Kalfarentzos F, Alexandrides TK (2012) Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg 22(11):1761–1770. https://doi.org/10.1007/s11695-012-0738-5
doi: 10.1007/s11695-012-0738-5
pubmed: 22911148
Lesti G, Aiolfi A, Mozzi E, Altorio F, Lattuada E, Lesti F, Bonitta G, Zappa MA (2018) Laparoscopic gastric bypass with fundectomy and gastric remnant exploration (LRYGBfse): results at 5-year follow-up. Obes Surg 28(9):2626–2633. https://doi.org/10.1007/s11695-018-3220-1
doi: 10.1007/s11695-018-3220-1
pubmed: 29623665
Denneval A, Chalumeau C, Iceta S, Pelascini E, Disse E, Robert M (2021) Revision of Mason’s procedure (vertical banded gastroplasty) to Roux-en-Y gastric bypass: role of an associated fundectomy in weight loss outcomes. Surg Obes Relat Dis 17(5):870–877. https://doi.org/10.1016/j.soard.2020.12.014
doi: 10.1016/j.soard.2020.12.014
pubmed: 33549506
McCarty TR, Jirapinyo P, Thompson CC (2020) Effect of sleeve gastrectomy on Ghrelin, GLP-1, PYY, and GIP gut hormones: a systematic review and meta-analysis. Ann Surg 272(1):72–80. https://doi.org/10.1097/SLA.0000000000003614
doi: 10.1097/SLA.0000000000003614
pubmed: 31592891
Sista F, Abruzzese V, Clementi M, Guadagni S, Montana L, Carandina S (2018) Resolution of type 2 diabetes after sleeve gastrectomy: a 2-step hypothesis. Surg Obes Relat Dis 14(3):284–290. https://doi.org/10.1016/j.soard.2017.12.009
doi: 10.1016/j.soard.2017.12.009
pubmed: 29339031
Cummings DE, Shannon MH (2003) Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 88(7):2999–3002. https://doi.org/10.1210/jc.2003-030705
doi: 10.1210/jc.2003-030705
pubmed: 12843132
Xu HC, Pang YC, Chen JW, Cao JY, Sheng Z, Yuan JH, Wang R, Zhang CS, Wang LX, Dong J (2019) Systematic review and meta-analysis of the change in Ghrelin levels after Roux-en-Y gastric bypass. Obes Surg 29(4):1343–1351. https://doi.org/10.1007/s11695-018-03686-3
doi: 10.1007/s11695-018-03686-3
pubmed: 30684171
Nosso G, Griffo E, Cotugno M, Saldalamacchia G, Lupoli R, Pacini G, Riccardi G, Angrisani L, Capaldo B (2016) Comparative effects of Roux-en-Y gastric bypass and sleeve gastrectomy on glucose homeostasis and incretin hormones in obese type 2 diabetic patients: a one-year prospective study. Horm Metab Res 48(5):312–317. https://doi.org/10.1055/s-0041-111505
doi: 10.1055/s-0041-111505
pubmed: 26788926
Alamri BN, Shin K, Chappe V, Anini Y (2016) The role of ghrelin in the regulation of glucose homeostasis. Horm Mol Biol Clin Investig 26(1):3–11. https://doi.org/10.1515/hmbci-2016-0018
doi: 10.1515/hmbci-2016-0018
pubmed: 27235674
Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Hofland LJ, Broglio F, Ghigo E, van der Lely AJ (2004) Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89(10):5035–5042. https://doi.org/10.1210/jc.2004-0363
doi: 10.1210/jc.2004-0363
pubmed: 15472202
Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, Abribat T, Van Der Lely AJ, Ghigo E (2004) Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 89(6):3062–3065. https://doi.org/10.1210/jc.2003-031964
doi: 10.1210/jc.2003-031964
pubmed: 15181099
Delhanty PJ, Huisman M, Baldeon-Rojas LY, van den Berge I, Grefhorst A, Abribat T, Leenen PJ, Themmen AP, van der Lely AJ (2013) Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis. FASEB J 27(4):1690–1700. https://doi.org/10.1096/fj.12-221143
doi: 10.1096/fj.12-221143
pubmed: 23299855
Granata R, Settanni F, Julien M, Nano R, Togliatto G, Trombetta A, Gallo D, Piemonti L, Brizzi MF, Abribat T, van Der Lely AJ, Ghigo E (2012) Des-acyl ghrelin fragments and analogues promote survival of pancreatic β-cells and human pancreatic islets and prevent diabetes in streptozotocin-treated rats. J Med Chem 55(6):2585–96. https://doi.org/10.1021/jm201223m
doi: 10.1021/jm201223m
pubmed: 22352743
Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D’Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Tschöp MH (2015) Ghrelin. Mol Metab 4(6):437–60. https://doi.org/10.1016/j.molmet.2015.03.005
doi: 10.1016/j.molmet.2015.03.005
pubmed: 26042199
pmcid: 4443295
Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschöp MH, D’Alessio D (2010) Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 59(9):2145–2151. https://doi.org/10.2337/db10-0504
doi: 10.2337/db10-0504
pubmed: 20584998
pmcid: 2927935
Flanagan DE, Evans ML, Monsod TP, Rife F, Heptulla RA, Tamborlane WV, Sherwin RS (2003) The influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 284(2):E313–E316. https://doi.org/10.1152/ajpendo.00569.2001
doi: 10.1152/ajpendo.00569.2001
pubmed: 12531744
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E (2001) Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86(10):5083–5086. https://doi.org/10.1210/jcem.86.10.8098
doi: 10.1210/jcem.86.10.8098
pubmed: 11600590
Muller AF, Lamberts SW, Janssen JA, Hofland LJ, Koetsveld PV, Bidlingmaier M, Strasburger CJ, Ghigo E, Van der Lely AJ (2002) Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol 146(2):203–207. https://doi.org/10.1530/eje.0.1460203
doi: 10.1530/eje.0.1460203
pubmed: 11834429
Li RL, Sherbet DP, Elsbernd BL, Goldstein JL, Brown MS, Zhao TJ (2012) Profound hypoglycemia in starved, ghrelin-deficient mice is caused by decreased gluconeogenesis and reversed by lactate or fatty acids. J Biol Chem 287(22):17942–50. https://doi.org/10.1074/jbc.M112.358051
doi: 10.1074/jbc.M112.358051
pubmed: 22474325
pmcid: 3365699
Colldén G, Tschöp MH, Müller TD (2017) Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 18(4):798. https://doi.org/10.3390/ijms18040798
doi: 10.3390/ijms18040798
pubmed: 28398233
pmcid: 5412382
Frezza EE, Wozniak SE, Gee L, Wacthel M (2009) Is there any role of resecting the stomach to ameliorate weight loss and sugar control in morbidly obese diabetic patients? Obes Surg 19(8):1139–1142. https://doi.org/10.1007/s11695-009-9868-9
doi: 10.1007/s11695-009-9868-9
pubmed: 19484314
Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flüe M, Beglinger C (2009) Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 250(2):234–241. https://doi.org/10.1097/SLA.0b013e3181ae32e3
doi: 10.1097/SLA.0b013e3181ae32e3
pubmed: 19638921
Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD (2011) Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 7(6):683–690. https://doi.org/10.1016/j.soard.2011.07.009
doi: 10.1016/j.soard.2011.07.009
pubmed: 21996600
Delko T, Köstler T, Peev M, Oertli D, Zingg U (2013) Influence of additional resection of the gastric fundus on excessive weight loss in laparoscopic very very long limb Roux-en-Y gastric bypass. Obes Surg 23(3):279–286. https://doi.org/10.1007/s11695-012-0805-y
doi: 10.1007/s11695-012-0805-y
pubmed: 23135881
Romero F, Nicolau J, Flores L, Casamitjana R, Ibarzabal A, Lacy A, Vidal J (2012) Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc 26(8):2231–2239. https://doi.org/10.1007/s00464-012-2166-y
doi: 10.1007/s00464-012-2166-y
pubmed: 22302537
Malin SK, Samat A, Wolski K, Abood B, Pothier CE, Bhatt DL, Nissen S, Brethauer SA, Schauer PR, Kirwan JP, Kashyap SR (2014) Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy. Int J Obes (Lond) 38(3):364–370. https://doi.org/10.1038/ijo.2013.196
doi: 10.1038/ijo.2013.196
pubmed: 24166065
Sista F, Abruzzese V, Clementi M, Carandina S, Amicucci G (2016) Effect of resected gastric volume on Ghrelin and GLP-1 Plasma levels: a prospective study. J Gastrointest Surg 20(12):1931–1941. https://doi.org/10.1007/s11605-016-3292-y
doi: 10.1007/s11605-016-3292-y
pubmed: 27738878
Santiago-Fernández C, García-Serrano S, Tome M, Valdes S, Ocaña-Wilhelmi L, Rodríguez-Cañete A, Tinahones FJ, García-Fuentes E, Garrido-Sánchez L (2017) Ghrelin levels could be involved in the improvement of insulin resistance after bariatric surgery. Endocrinol Diabetes Nutr 64(7):355–362. https://doi.org/10.1016/j.endinu.2017.05.002 . (English, Spanish)
doi: 10.1016/j.endinu.2017.05.002
pubmed: 28745606
Wallenius V, Dirinck E, Fändriks L, Maleckas A, le Roux CW, Thorell A (2018) Glycemic control after sleeve gastrectomy and Roux-En-Y gastric bypass in obese subjects with type 2 diabetes mellitus. Obes Surg 28(6):1461–1472. https://doi.org/10.1007/s11695-017-3061-3
doi: 10.1007/s11695-017-3061-3
pubmed: 29264780
Casajoana A, Pujol J, Garcia A, Elvira J, Virgili N, de Oca FJ, Duran X, Fernández-Veledo S, Vendrell J, Vilarrasa N (2017) Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg 27(9):2235–2245. https://doi.org/10.1007/s11695-017-2669-7
doi: 10.1007/s11695-017-2669-7
pubmed: 28451931
Casajoana A, Guerrero-Pérez F, Ruiz G, de Gordejuela A, Admella V, Sorribas M, Vidal-Alabró A, Virgili N, Urdiales RL, Montserrat M, Pérez-Maraver M, Monasterio C, Salord N, Pellitero S, Fernández-Veledo S, Vendrell J, Gebelli JP, Vilarrasa N (2021) Role of gastrointestinal hormones as a predictive factor for long-term diabetes remission: randomized trial comparing metabolic gastric bypass, sleeve gastrectomy, and greater curvature plication. Obes Surg 31(4):1733–1744. https://doi.org/10.1007/s11695-020-05192-x
doi: 10.1007/s11695-020-05192-x
pubmed: 33398627
Fatima F, Hjelmesæth J, Birkeland KI, Gulseth HL, Hertel JK, Svanevik M, Sandbu R, Småstuen MC, Hartmann B, Holst JJ, Hofsø D (2022) Gastrointestinal hormones and β-cell function after gastric bypass and sleeve gastrectomy: a randomized controlled trial (oseberg). J Clin Endocrinol Metab 107(2):e756–e766. https://doi.org/10.1210/clinem/dgab643
doi: 10.1210/clinem/dgab643
pubmed: 34463768
Batterham RL, Cummings DE (2016) Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 39(6):893–901. https://doi.org/10.2337/dc16-0145
doi: 10.2337/dc16-0145
pubmed: 27222547
pmcid: 5864134
Sista F, Abruzzese V, Clementi M, Carandina S, Cecilia M, Amicucci G (2017) The effect of sleeve gastrectomy on GLP-1 secretion and gastric emptying: a prospective study. Surg Obes Relat Dis 13(1):7–14. https://doi.org/10.1016/j.soard.2016.08.004
doi: 10.1016/j.soard.2016.08.004
pubmed: 27692912
Dirksen C, Jørgensen NB, Bojsen-Møller KN, Jacobsen SH, Hansen DL, Worm D, Holst JJ, Madsbad S (2012) Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 55(7):1890–1901. https://doi.org/10.1007/s00125-012-2556-7
doi: 10.1007/s00125-012-2556-7
pubmed: 22538359
van der Lely AJ, Tschöp M, Heiman ML, Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25(3):426–457. https://doi.org/10.1210/er.2002-0029
doi: 10.1210/er.2002-0029
pubmed: 15180951
Sakata I, Sakai T (2010) Ghrelin cells in the gastrointestinal tract. Int J Pept 2010:945056. https://doi.org/10.1155/2010/945056
doi: 10.1155/2010/945056
pubmed: 20798855
pmcid: 2925405
Park JM, Kakimoto T, Kuroki T, Shiraishi R, Fujise T, Iwakiri R, Fujimoto K (2008) Suppression of intestinal mucosal apoptosis by ghrelin in fasting rats. Exp Biol Med (Maywood) 233(1):48–56. https://doi.org/10.3181/0706-RM-169
doi: 10.3181/0706-RM-169
pubmed: 18156305
Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, Gfrerer L, Ludvik B, Zacherl J, Prager G (2010) Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg 20(5):535–540. https://doi.org/10.1007/s11695-009-0066-6
doi: 10.1007/s11695-009-0066-6
pubmed: 20094819
Yu J, Zhou X, Li L, Li S, Tan J, Li Y, Sun X (2015) The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg 25(1):143–158. https://doi.org/10.1007/s11695-014-1460-2
doi: 10.1007/s11695-014-1460-2
pubmed: 25355456
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR, STAMPEDE Investigators (2017) Bariatric Surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 376(7):641–651. https://doi.org/10.1056/NEJMoa1600869
doi: 10.1056/NEJMoa1600869
pubmed: 28199805
pmcid: 5451258
Borgeraas H, Hofsø D, Hertel JK, Hjelmesaeth J (2020) Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Obes Rev 21(6):e13011. https://doi.org/10.1111/obr.13011
doi: 10.1111/obr.13011
pubmed: 32162437
pmcid: 7317556
Panunzi S, Carlsson L, De Gaetano A, Peltonen M, Rice T, Sjöström L, Mingrone G, Dixon JB (2016) Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 39(1):166–174. https://doi.org/10.2337/dc15-0575
doi: 10.2337/dc15-0575
pubmed: 26628418